medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2015, Número 3

<< Anterior Siguiente >>

Residente 2015; 10 (3)


Interleucina-18 en síndrome metabólico

Dávalos-de la Cruz AP, Flores-Chávez A, Hernández-Cuervo P, Ramírez-Villafaña M, González-Ponce F, Bonilla-Lara D, Contreras-Moreno MG, Trujillo-Hernández B, Gámez-Nava JI

Idioma: Español
Referencias bibliográficas: 36
Paginas: 118-124
Archivo PDF: 226.15 Kb.


RESUMEN

El síndrome metabólico (SM) es una entidad que se presenta con una frecuencia de 41.6% en mexicanos, se asocia a un estado de inflamación crónico en el que múltiples citocinas están implicadas. Este artículo de revisión describe la evidencia científica actual que sugiere que la interleucina-18 (IL-18) podría estar estrechamente relacionada con el SM y sus consecuencias. Se ha observado un incremento de los niveles séricos de IL-18 en el SM y detectado expresión de IL-18 en la placa ateroesclerótica inestable en el tejido adiposo y en el tejido muscular. Este artículo aborda además los aspectos patogénicos en el que IL-18 pudiese tener un papel en el desarrollo del SM.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002; 156: 1070-1077.

  2. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, Morelos: Instituto Nacional de Salud Pública (MX); 2012.

  3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001; 285 (19): 2486-2497.

  4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645.

  5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine. 1998; 15 (7): 539-553.

  6. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabetic Medicine. 1999; 16 (5): 442-443.

  7. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. Available in: http://www.idf.org/metabolic-syndrome.

  8. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003; 9 (3): 237-252.

  9. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112: 3066-3072.

  10. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. J Am Med Assoc. 1999; 282: 2131-2135.

  11. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006; 83: 447S-455S.

  12. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007; 27: 98-114.

  13. Shaw MH, Reimer T, Kim YG, Nuñez G. NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol. 2008; 20: 377-382.

  14. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999; 10: 127-136.

  15. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001; 12: 53-72.

  16. Bosch M, Lopez-Bermejo A, Vendrell J, Musri M, Ricart W et al. Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetología. 2005; 48: 1841-1843.

  17. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005; 25: 1268-1273.

  18. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002. Diabetes. 2005; 54: 2932-2938.

  19. Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB. Circulating IL-18 and the risk of type 2 diabetes in women. Diabetología. 2009; 52: 2101-2108.

  20. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring). 2006; 14: 2127-2131.

  21. He M, Cornelis MC, Kraft P, van Dam RM, Sun Q, Laurie CC et al. Genome wide association study identifies variants at the IL18-BCO2 locus associated with interleukin-18 levels. Arterioscler Thromb Vasc Biol. 2010; 30 (4): 885-890.

  22. Smart MC, Dedoussis G, Yiannakouris N, Grisoni ML, Dror GK, Yannakoulia M et al. Genetic variation within IL18 is associated with insulin levels, insulin resistance and postprandial measures. Nutr Metab Cardiovasc Dis. 2011; 21 (7): 476-484.

  23. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005; 25: 1268-1273.

  24. Yamaoka-Tojo M, Tojo T, Wakaume K, Kameda R, Nemoto S, Takahira N et al. Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome. Nutr Metab (Lond). 2001; 8: 3.

  25. Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB. Circulating IL-18 and the risk of type 2 diabetes in women. Diabetología. 2009; 52 (10): 2101-2108.

  26. Sun L, Hu FB, Yu Z, Li H, Liu H, Wang X et al. Lean body mass, interleukin 18, and metabolic syndrome in apparently healthy Chinese. PLoS One. 2011; 6 (3): e18104.

  27. Everett BM, Bansal S, Rifai N, Buring JE, Ridker PM. Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis. 2009; 202 (1): 282-288.

  28. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol. 2008; 28: 1304-1310.

  29. Bruun JM, Stallknecht B, Helge JW, Richelsen B. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol. 2007; 157: 465-471.

  30. Troseid M, Lappegard KT, Mollnes TE, Arnesen H, Seljeflot I. The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome. Metab Syndr Relat Disord. 2009; 7: 579-584.

  31. Deen D. Metabolic syndrome: time for action. Am Fam Physician. 2004; 69 (12): 2875-2887.

  32. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112 (17): 2735-2752.

  33. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 1987; 147 (10): 1749-1753.

  34. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37 (12): 1595-1607.

  35. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014; 2014: 943162.

  36. Bellentani S, Dalle-Grave R, Suppini A, Marchesini G; Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008; 47 (2): 746-754.




2020     |     www.medigraphic.com